JP7045795B2 - 結晶性β－ラクタマーゼ阻害剤 - Google Patents

結晶性β－ラクタマーゼ阻害剤 Download PDF

Info

Publication number
JP7045795B2
JP7045795B2 JP2016527458A JP2016527458A JP7045795B2 JP 7045795 B2 JP7045795 B2 JP 7045795B2 JP 2016527458 A JP2016527458 A JP 2016527458A JP 2016527458 A JP2016527458 A JP 2016527458A JP 7045795 B2 JP7045795 B2 JP 7045795B2
Authority
JP
Japan
Prior art keywords
methyl
heptane
ium
thia
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016527458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535054A (ja
JP2016535054A5 (enExample
Inventor
ラモニカ，アレッサンドロ
フォーザッティ，マルコ
ビオンディ，ステファノ
Original Assignee
アレクラ セラピューティクス ソシエテ パール アクシオン シンプリフィエ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49818360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7045795(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アレクラ セラピューティクス ソシエテ パール アクシオン シンプリフィエ filed Critical アレクラ セラピューティクス ソシエテ パール アクシオン シンプリフィエ
Publication of JP2016535054A publication Critical patent/JP2016535054A/ja
Publication of JP2016535054A5 publication Critical patent/JP2016535054A5/ja
Priority to JP2021052653A priority Critical patent/JP7346485B2/ja
Application granted granted Critical
Publication of JP7045795B2 publication Critical patent/JP7045795B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016527458A 2013-11-08 2014-11-07 結晶性β－ラクタマーゼ阻害剤 Active JP7045795B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021052653A JP7346485B2 (ja) 2013-11-08 2021-03-26 結晶性β－ラクタマーゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1319776.9A GB201319776D0 (en) 2013-11-08 2013-11-08 Compound
GB1319776.9 2013-11-08
GBGB1408643.3A GB201408643D0 (en) 2013-11-08 2014-05-15 Compound
GB1408643.3 2014-05-15
PCT/EP2014/074108 WO2015067787A1 (en) 2013-11-08 2014-11-07 Crystalline beta-lactamase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021052653A Division JP7346485B2 (ja) 2013-11-08 2021-03-26 結晶性β－ラクタマーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2016535054A JP2016535054A (ja) 2016-11-10
JP2016535054A5 JP2016535054A5 (enExample) 2017-12-14
JP7045795B2 true JP7045795B2 (ja) 2022-04-01

Family

ID=49818360

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016527458A Active JP7045795B2 (ja) 2013-11-08 2014-11-07 結晶性β－ラクタマーゼ阻害剤
JP2021052653A Active JP7346485B2 (ja) 2013-11-08 2021-03-26 結晶性β－ラクタマーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021052653A Active JP7346485B2 (ja) 2013-11-08 2021-03-26 結晶性β－ラクタマーゼ阻害剤

Country Status (14)

Country Link
US (2) US20160289245A1 (enExample)
EP (1) EP3066103A1 (enExample)
JP (2) JP7045795B2 (enExample)
KR (1) KR20160081964A (enExample)
CN (1) CN105873935B (enExample)
AU (1) AU2014345507B2 (enExample)
CA (1) CA2929199C (enExample)
CL (1) CL2016001097A1 (enExample)
EA (1) EA031348B1 (enExample)
GB (2) GB201319776D0 (enExample)
IL (1) IL245386A0 (enExample)
MX (1) MX2016005869A (enExample)
PE (1) PE20160890A1 (enExample)
WO (1) WO2015067787A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
WO2026086730A1 (zh) * 2024-10-21 2026-04-30 齐鲁制药有限公司 恩美他唑巴坦的晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010048A2 (en) 2006-07-12 2008-01-24 Orchid Chemicals & Pharmaceuticals Limited Novel 2-substituted methyl penam derivatives
JP2021102642A (ja) 2013-11-08 2021-07-15 アレクラ セラピューティクス ソシエテ パール アクシオン シンプリフィエ 結晶性β−ラクタマーゼ阻害剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US6156745A (en) * 1997-12-29 2000-12-05 Research Corporation Technologies, Inc. 2β-substituted-6-alkylidene penicillanic acid derivatives as β-lactamase inhibitors
US7273935B2 (en) * 2003-08-21 2007-09-25 Orchid Chemicals & Pharmaceuticals, Ltd. Process for the preparation of 3-methylcepham derivatives
US7417143B2 (en) * 2004-04-07 2008-08-26 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of Tazobactam in pure form
NZ610247A (en) * 2010-11-25 2014-09-26 Allecra Therapeutics Gmbh Β-lactamase inhibitors and their use
EP2847205A4 (en) * 2012-05-07 2016-01-20 Univ California NOVEL OXYSTEROL ANALOGUE OXY149 FOR THE INDUCTION OF OSTEOGENESIS AND HEDGEHOG SIGNAL PATH AND THE INHIBITION OF ADIPOGENESIS
US9683009B2 (en) * 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
KR20170101940A (ko) * 2014-12-09 2017-09-06 워쏘우 오르쏘페딕 인코포레이티드 스테롤 관련 화합물 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010048A2 (en) 2006-07-12 2008-01-24 Orchid Chemicals & Pharmaceuticals Limited Novel 2-substituted methyl penam derivatives
JP2021102642A (ja) 2013-11-08 2021-07-15 アレクラ セラピューティクス ソシエテ パール アクシオン シンプリフィエ 結晶性β−ラクタマーゼ阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｓｔｅｐｈｅｎ ＢＹＲＮ ｅｔ ａｌ，Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｓｏｌｉｄｓ： Ａ Ｓｔｒａｔｅｇｉｃ Ａｐｐｒｏａｃｈ ｔｏ Ｒｅｇｕｌａｔｏｒｙ Ｃｏｎｓｉｄｅｒａｔｉｏｎｓ，Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｒｅｓｅａｒｃｈ，１９９５年 ７月，Ｖｏｌ．１２， Ｎｏ．７，ｐ．９４５－９５４
平山令明，有機化合物結晶作製ハンドブック－原理とノウハウ－，丸善株式会社，２００８年 ７月２５日，ｐ．１７－２３，３７－４０，４５－５１，５７－６５

Also Published As

Publication number Publication date
EP3066103A1 (en) 2016-09-14
GB201319776D0 (en) 2013-12-25
CA2929199A1 (en) 2015-05-14
GB201408643D0 (en) 2014-07-02
US20190071456A1 (en) 2019-03-07
CN105873935B (zh) 2019-03-19
CA2929199C (en) 2023-01-03
CL2016001097A1 (es) 2016-12-02
AU2014345507A1 (en) 2016-05-19
WO2015067787A1 (en) 2015-05-14
JP2016535054A (ja) 2016-11-10
US20160289245A1 (en) 2016-10-06
AU2014345507B2 (en) 2018-11-22
JP2021102642A (ja) 2021-07-15
EA031348B1 (ru) 2018-12-28
JP7346485B2 (ja) 2023-09-19
KR20160081964A (ko) 2016-07-08
PE20160890A1 (es) 2016-08-25
CN105873935A (zh) 2016-08-17
MX2016005869A (es) 2017-01-05
US11124526B2 (en) 2021-09-21
IL245386A0 (en) 2016-06-30
EA201690963A1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
JP2011506374A (ja) テノホビルジソプロキシルの固形物
JP6660399B2 (ja) ブプレノルフィンの酢酸塩及びブプレノルフィンの調製方法
RU2703457C2 (ru) Твёрдые формы цефтолозана
CN107001366B (zh) 二氮杂二环辛烷衍生物的结晶以及稳定的冻干制剂的制备方法
US8476425B1 (en) Tazobactam arginine compositions
US20190282546A1 (en) Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
EP3229791A2 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
JP7346485B2 (ja) 結晶性β－ラクタマーゼ阻害剤
CA2894935A1 (en) Novel crystalline forms of ceftaroline fosamil
JP4130078B2 (ja) カルバペネム誘導体結晶と注射製剤
RU2074858C1 (ru) Кристаллический дигидрат (5r, 6s)-2-карбамоилоксиметил-6-[(1r)-гидроксиэтил]-2-пенем-3-карбоновой кислоты, способ его получения, фармацевтическая композиция
BR112016010282B1 (pt) Composição farmacêutica compreendendo um inibidor de betalactamase cristalino
WO2026086730A1 (zh) 恩美他唑巴坦的晶型及其制备方法
US20230075170A1 (en) Novel salts of nilotinib and polymorphic forms thereof
AU2013204129C1 (en) Crystal Form of Quinoline Compound and Process for its Production
EP3441395A1 (en) Method for preparing penams
JP3900302B2 (ja) 結晶性ｌ−アスパラギン酸カルシウムの製造方法
JP2010013356A (ja) 結晶性カルバペネム化合物
WO2019151133A1 (ja) ボルテゾミブ結晶の製造方法
KR20100098439A (ko) β-락탐 화합물의 안정형 결정

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191108

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191118

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20191119

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200124

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200128

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200707

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200929

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220125

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220222

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220322

R150 Certificate of patent or registration of utility model

Ref document number: 7045795

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250